Human β-defensin-2 production upon viral and bacterial co-infection is attenuated in COPD

PLoS One. 2017 May 10;12(5):e0175963. doi: 10.1371/journal.pone.0175963. eCollection 2017.

Abstract

Viral-bacterial co-infections are associated with severe exacerbations of COPD. Epithelial antimicrobial peptides, including human β-defensin-2 (HBD-2), are integral to innate host defenses. In this study, we examined how co-infection of airway epithelial cells with rhinovirus and Pseudomonas aeruginosa modulates HBD-2 expression, and whether these responses are attenuated by cigarette smoke and in epithelial cells obtained by bronchial brushings from smokers with normal lung function or from COPD patients. When human airway epithelial cells from normal lungs were infected with rhinovirus, Pseudomonas aeruginosa, or the combination, co-infection with rhinovirus and bacteria resulted in synergistic induction of HBD-2 (p<0.05). The combination of virus and flagellin replicated this synergistic increase (p<0.05), and synergy was not seen using a flagella-deficient mutant Pseudomonas (p<0.05). The effects of Pseudomonas aeruginosa were mediated via interactions of flagellin with TLR5. The effects of HRV-16 depended upon viral replication but did not appear to be mediated via the intracellular RNA helicases, retinoic acid-inducible gene-I or melanoma differentiation-associated gene-5. Cigarette smoke extract significantly decreased HBD-2 production in response to co-infection. Attenuated production was also observed following co-infection of cells obtained from healthy smokers or COPD patients compared to healthy controls (p<0.05). We conclude that co-exposure to HRV-16 and Pseudomonas aeruginosa induces synergistic production of HBD-2 from epithelial cells and that this synergistic induction of HBD-2 is reduced in COPD patients. This may contribute to the more severe exacerbations these patients experience in response to viral-bacterial co-infections.

MeSH terms

  • Bacterial Infections / complications*
  • Bacterial Infections / metabolism
  • Cells, Cultured
  • Gene Knockdown Techniques
  • Humans
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / metabolism*
  • Smoking
  • Toll-Like Receptor 5 / genetics
  • Virus Diseases / complications*
  • Virus Diseases / metabolism
  • beta-Defensins / biosynthesis*

Substances

  • TLR5 protein, human
  • Toll-Like Receptor 5
  • beta-Defensins

Grants and funding

Grant numbers 82049 (to RL) & 43923 (to DP) from the Canadian Institutes of Health Research (CIHR) supported this work. Dr. Leigh holds the GlaxoSmithKline-CIHR Professorship in Inflammatory Lung Diseases at the University of Calgary and Dr. Proud is the recipient of a Tier 1 Canada Research Chair in Inflammatory Airway Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.